Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 14/20 | 0.43 |
| ▸ | JAK2 | O60674 | 10/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21757048 | 0.91 | JAK1 (0.45) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL21756990 | 0.86 | JAK1 (0.42) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL22754610 | 0.84 | JAK1 (0.43) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL20082889 | 0.84 | JAK1 (0.48) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL6421780 | 0.83 | ALDH1A1 (0.58) | JAK2JAK3ALDH1A1NPC1KDM4E | |
| SCHEMBL12424412 | 0.76 | KDM4E (0.45) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL22007006 | 0.76 | JAK1 (0.49) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL21757053 | 0.75 | JAK2 (0.43) | JAK1JAK2TYK2ALDH1A1NPC1 | |
| SCHEMBL19159529 | 0.75 | JAK3 (0.47) | JAK1JAK2TYK2JAK3ALDH1A1 | |
| SCHEMBL27253737 | 0.74 | USP2 (0.49) | ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4105214-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | Zhuhai United Laboratories Co., Ltd (CN) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022161205-A1 | ORAL PREPARATION CONTAINING JAK INHIBITOR OR SALT THEREOF OR CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2021159372-A1 | USE OF JAK INHIBITORS IN PREPARATION OF DRUGS FOR TREATING JAK KINASE-RELATED DISEASES | 珠海联邦制药股份有限公司 | 2021-08-19 | — | — | WO | disclosed |
| EP-3842431-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | Zhuhai United Laboratories Co., Ltd (CN) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020038457-A1 | [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF | 珠海联邦制药股份有限公司 | 2020-02-27 | — | — | WO | disclosed |
| US-9403829-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2016-08-02 | — | — | US | disclosed |